Kardigan, Inc.
corporate_fare Company Profile
Kardigan, Inc. (NASDAQ:KARD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for KARD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-11, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for KARD spans 10-Q, 8-K, SCHEDULE 13D, 424B4.
Recent high-impact activity:
- Kardigan Q2 2026: $116.2M net loss despite $660.7M cash cushion; $43.5M non-cash charge tied to milestone revaluation
- Kardigan Reports Q2 2026 Results: $660.7M Cash, Three Phase 2/3 Trials Advancing
- Kardigan Reports $661M Cash, Advances Three Late-Stage Heart Programs
- ARCH Venture Fund Discloses 16.2% Stake in Kardigan Post-IPO, Including Recent $20M Purchase
- Perceptive Advisors Discloses 8.9% Stake in Kardigan Post-IPO
Short Interest & Short Volume
6.30 days to coverFINRA reported short interest of 2,568,799 shares in KARD as of the September 15, 2026 settlement, a 16.3% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On October 2, 2026, 82.5% of KARD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for KARD, detected from its recent SEC filings · based on capital-structure filings through 2026-06-18.
Initial Public Offering Priced · Significant Capital Raise
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →